Benjamin Jackson CFA
Stock Analyst at Jefferies
(3.36)
# 2,372
Out of 4,476 analysts
84
Total ratings
53.3%
Success rate
7.7%
Average return
Main Sectors:
Stocks Rated by Benjamin Jackson CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SWX: GALD Galderma Group AG | Maintained: Buy | CHF 205.00 | $179.55 | +14.17% | 31 | Jul 1, 2026 | |
| LON: 0DPB Bavarian Nordic A/S | Maintained: Buy | kr 275.00 → kr 280.00 | $190.90 | +46.67% | 2 | May 19, 2026 | |
| EPA: IPN Ipsen S.A. | Maintained: Hold | €117.00 | $170.70 | -31.46% | 2 | May 17, 2026 | |
| ZLDPF Zealand Pharma A/S | Maintained: Buy | $77 | $46.95 | +64.58% | 2 | Apr 19, 2026 | |
| SWX: COPN Cosmo N.V. | Maintained: Buy | CHF 150.00 → CHF 140.00 | $70.50 | +98.58% | 2 | Mar 25, 2026 | |
| GMAB Genmab | Initiated Coverage: Buy | $42 | $28.52 | +45.54% | 1 | Feb 17, 2026 | |
| LON: 0MGB Genmab A/S | Initiated Coverage: Buy | kr 2,650 | $1,861.29 | +42.37% | 1 | Feb 16, 2026 | |
| SWX: NOVN Novartis AG | Maintained: Hold | CHF 110.00 | $127.92 | -14.01% | 5 | Feb 4, 2026 | |
| EPA: SAN Sanofi | Maintained: Buy | €100.00 | $75.81 | +31.91% | 9 | Dec 29, 2025 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Sell | kr 415.00 → kr 290.00 | $326.48 | -11.17% | 7 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | CHF 270.00 → CHF 230.00 | $340.60 | -32.47% | 6 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | 1,450p | $2,015.00 | -28.04% | 2 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | 10,900p | $14,456.00 | -24.60% | 2 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $28 | $38.89 | n/a | 1 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €6.80 | $5.14 | n/a | 10 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $3.8 | $2.90 | n/a | 1 | Oct 7, 2024 |
Galderma Group AG
Jul 1, 2026
Maintained: Buy
Price Target: CHF 205.00
Current: $179.55
Upside: +14.17%
Bavarian Nordic A/S
May 19, 2026
Maintained: Buy
Price Target: kr 275.00 → kr 280.00
Current: $190.90
Upside: +46.67%
Ipsen S.A.
May 17, 2026
Maintained: Hold
Price Target: €117.00
Current: $170.70
Upside: -31.46%
Zealand Pharma A/S
Apr 19, 2026
Maintained: Buy
Price Target: $77
Current: $46.95
Upside: +64.58%
Cosmo N.V.
Mar 25, 2026
Maintained: Buy
Price Target: CHF 150.00 → CHF 140.00
Current: $70.50
Upside: +98.58%
Genmab
Feb 17, 2026
Initiated Coverage: Buy
Price Target: $42
Current: $28.52
Upside: +45.54%
Genmab A/S
Feb 16, 2026
Initiated Coverage: Buy
Price Target: kr 2,650
Current: $1,861.29
Upside: +42.37%
Novartis AG
Feb 4, 2026
Maintained: Hold
Price Target: CHF 110.00
Current: $127.92
Upside: -14.01%
Sanofi
Dec 29, 2025
Maintained: Buy
Price Target: €100.00
Current: $75.81
Upside: +31.91%
Novo Nordisk A/S
Oct 27, 2025
Maintained: Sell
Price Target: kr 415.00 → kr 290.00
Current: $326.48
Upside: -11.17%
Oct 27, 2025
Downgraded: Sell
Price Target: CHF 270.00 → CHF 230.00
Current: $340.60
Upside: -32.47%
Jul 30, 2025
Maintained: Hold
Price Target: 1,450p
Current: $2,015.00
Upside: -28.04%
Jul 29, 2025
Maintained: Hold
Price Target: 10,900p
Current: $14,456.00
Upside: -24.60%
Jan 31, 2025
Upgraded: Buy
Price Target: $28
Current: $38.89
Upside: n/a
Nov 13, 2024
Maintained: Hold
Price Target: €6.80
Current: $5.14
Upside: n/a
Oct 7, 2024
Downgraded: Hold
Price Target: $3.8
Current: $2.90
Upside: n/a